Systematic genome editing of the genes on zebrafish Chromosome 1 by CRISPR/Cas9

Yonghua Sun,¹ Bo Zhang,² Lingfei Luo,³ De-Li Shi,⁴ Han Wang,⁵ Zongbin Cui,¹ Honghui Huang,³ Ying Cao,⁶ Xiaodong Shu,⁷ Wenqing Zhang,⁸ Jianfeng Zhou,⁹ Yun Li,⁹ Jiulin Du,¹⁰ Qingshun Zhao,¹¹ Jun Chen,¹² Hanbing Zhong,¹³ Tao P. Zhong,¹⁴ Li Li,³ Jing-Wei Xiong,¹⁵ Jinrong Peng,¹² Wuhan Xiao,¹ Jian Zhang,¹⁶ Jihua Yao,¹⁷ Zhan Yin,¹ Xianming Mo,¹⁸ Gang Peng,¹⁹ Jun Zhu,²⁰ Yan Chen,²¹ Yong Zhou,²² Dong Liu,¹³ Weijun Pan,²² Yiyue Zhang,⁸ Hua Ruan,³ Feng Liu,²³ Zuoyan Zhu,¹ Anming Meng,²⁴ and The ZAKOC Consortium²⁵

¹State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Innovation Academy for Seed Design, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China; ²Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, Peking University Genome Editing Research Center, College of Life Sciences, Peking University, Beijing, 100871, China; ³School of Life Sciences, Southwest University, Chongqing, 400715, China; ⁴Guangdong Medical University, Zhanjiang, Guangdong, 524023, China; ⁵Center for Circadian Clocks, Soochow University, Suzhou, Jiangsu, 215123, China; ⁶School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China; ⁷Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, 510530, China; ⁸Division of Cell, Developmental and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; ⁹School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, 266100, China; ¹⁰State Key Laboratory of Neuroscience, Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, 200031, China; ¹¹Model Animal Research Center, Nanjing University, Nanjing, Jiangsu, 210093, China; ¹²College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, China; ¹³Department of Biology, South University of Science and Technology of China, Shenzhen, Guangdong, 518055, China; ¹⁴Institute of Biomedical Sciences, East China Normal University, Shanghai, 200062, China; ¹⁵College of Life Sciences, Institute of Molecular Medicine, Peking University, Beijing, 100871, China; ¹⁶School of Life Sciences, Yunnan University, Kunming, Yunnan, 650091, China; ¹⁷School of Life Sciences, Fudan University, Shanghai, 200433, China; ¹⁸State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; ¹⁹Institutes of Brain Science, Fudan University, Shanghai, 200433, China; ²⁰Sino-French Research Center for Life Sciences and Genomics, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; ²¹Institute of Health Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; ²²CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, 200031, China; ²³State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China; ²⁴School of Life Sciences, Tsinghua University, Beijing, 100084, China

Genome editing by the well-established CRISPR/Cas9 technology has greatly facilitated our understanding of many biological processes. However, a complete whole-genome knockout for any species or model organism has rarely been achieved. Here, we performed a systematic knockout of all the genes (1333) on Chromosome 1 in zebrafish, successfully mutated 1029 genes, and generated 1039 germline-transmissible alleles corresponding to 636 genes. Meanwhile, by high-throughput bioinformatics analysis, we found that sequence features play pivotal roles in effective gRNA targeting at specific genes of interest, while the success rate of gene targeting positively correlates with GC content of the target sites. Moreover, we found that nearly one-fourth of all mutants are related to human diseases, and several representative CRISPR/Cas9-generated mutants are described here. Furthermore, we tried to identify the underlying mechanisms leading to distinct phenotypes between genetic mutants and antisense morpholino-mediated knockdown embryos. Altogether, this work has generated the first chromosome-wide collection of zebrafish genetic mutants by the CRISPR/Cas9 technology, which will serve as a valuable resource for the community, and our bioinformatics analysis also provides some useful guidance to design gene-specific gRNAs for successful gene editing.

[Supplemental material is available for this article.]

²⁵A complete list of the ZAKOC Consortium authors appears at the end of this paper.

Corresponding authors: liuf@ioz.ac.cn, zyzhu@ihb.ac.cn, mengam@mail.tsinghua.edu.cn

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.248559.119>. Freely available online through the *Genome Research* Open Access option.

© 2020 Sun et al. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

Zebrafish (*Danio rerio*) has been extensively used as a vertebrate model organism in developmental biology and genetic studies, partly due to the transparency of the early embryos and feasibility of obtaining a large quantity of progeny. In the past decades, large-scale investigation of gene function in development and genetics has been achieved primarily through N-ethyl-N-nitrosourea (ENU)-mediated mutagenesis (Solnica-Krezel et al. 1994) and retroviral mutagenesis (Amsterdam et al. 1999; Golling et al. 2002), also referred to as ‘forward’ genetics (from phenotypes to genes) (Huang et al. 2012). Compared to a ‘forward’ genetic study, ‘reverse’ genetics (from genes to phenotypes) can precisely mutate the target sites of interest in the genome and systematically identify the mutated phenotypes (Wienholds et al. 2003; Kettleborough et al. 2013; Varshney et al. 2013). Currently, with the development and application of engineered endonucleases, including zinc finger nucleases (ZFN) (Doyon et al. 2008), transcription activator-like effector nucleases (TALEN) (Moore et al. 2012), and the CRISPR/Cas system (such as the CRISPR/Cas9 system) (Li et al. 2016; Varshney et al. 2016), the ‘reverse’ genetic study has evolved rapidly. The flexibility of the CRISPR/Cas9 system and data from the completed zebrafish genome sequencing project make it possible to systematically knock out every single gene in zebrafish (Howe et al. 2013; Hwang et al. 2013; Varshney et al. 2015). However, properties of gene targeting via the CRISPR/Cas9, such as the sequence bias of targetable or highly efficient sites, remain elusive and need to be substantially characterized.

To generate a comprehensive genetic resource to facilitate zebrafish research for the community, we aim to knock out all the annotated genes in zebrafish Chromosome 1, a project involving 38 laboratories from 24 institutions in China. To our knowledge, this is the first report on systematic genome targeting spanning an entire chromosome of an organism in vertebrates with the use of the CRISPR/Cas9 technology.

Results

Selection of target genes on zebrafish Chromosome 1

The ~1.5-giga base-pair (Gbp) haploid nuclear genome of zebrafish comprises 25 chromosomes (Howe et al. 2013). It is estimated that there are ~32,000 genes in the genome, including ~26,000 coding genes and ~6000 noncoding genes, and roughly 1300 genes per chromosome on average. The size of Chromosome 1 of zebrafish was reported to be about 60 mega base-pairs (Mbp), constituting ~4% of the whole genome and containing 1418 genes (according to Zv9 release 60, 2013-01) (Table 1). Except for seven pseudogenes

Table 1. Selection of target genes on zebrafish Chromosome 1

Gene classification	Gene counts ^a	Selected for targeting
Pseudogene	7	0
Coding gene	1202	1202
Noncoding gene: housekeeping	99	21 ^b
Noncoding gene: miRNA	31	31
Noncoding gene: lincRNA	6	6
Noncoding gene: other	73	73
Sum	1418	1333

^aBased on Zv9 release 60, 2013-01.

^bSeventy-eight rRNA genes were excluded from our project.

Table 2. Status of zebrafish Chromosome 1 mutations

	Gene number	Allele number
Total tested	1333	
F ₀ positive	1029	
F ₁ positive	636	1039
F ₂ positive	452	703
CZRC preserved	491	693

and 78 rRNA genes present on Chromosome 1, a total of 1333 genes were considered for the gene targeting attempts, consisting of 1202 coding genes and 131 noncoding genes (including 31 microRNAs and six long intergenic noncoding RNAs) (Table 1). For convenience, all of the selected target genes were numbered according to their order along Chromosome 1, with the prefix “zko.” A full list of the zko genes can be found in the Supplemental Data (Supplemental Table S1).

Among these 1333 target genes (zko genes), only 109 genes had been studied with morpholino (MO) antisense oligonucleotides, 690 genes were recorded to have mutated/modified alleles in the zebrafish information network (ZFIN), an open-access online database for zebrafish research, and mutations for 606 genes had been identified from the Sanger Institute Zebrafish Mutation Project (Supplemental Table S1), while the majority of the target genes had not been subjected to mutational analysis. Furthermore, most of the mutated genes are coding genes, whereas only 39 noncoding genes had available mutations, most of which are point mutations generated through ENU mutagenesis.

Summary of targeted genes/mutations on zebrafish Chromosome 1

In order to disrupt the target genes completely, we adopted the strategy of using a single gRNA to generate indel mutations for the coding genes and a pair of gRNAs to produce genomic deletions for the noncoding genes (Supplemental Fig. S1). As to some coding genes, several gRNAs were designed and validated at the same time. Therefore, at least one gRNA for each coding gene and one pair of gRNAs for each noncoding gene was designed and tested. In rare cases, more than 10 gRNAs were designed and tested for one coding gene, such as *zko187* (*chtf18*), since none of the 10 gRNAs gave positive results.

Up until now, 1029 (77.2%) out of 1333 zko genes have been successfully mutated. Mutations were detected at least in founder embryos after injection of gRNA(s) together with Cas9 mRNA, including 962 coding genes and 67 noncoding genes. Mutations for 438 genes are first reported in this study. In total, 2277 gRNAs have been designed and tested, and 1086 (47.8%) among them showed to be efficient (Supplemental Table S1). After screening the inheritance of mutant alleles, we have successfully obtained 1039 germ-line mutant alleles in 636 genes (61.8% against 1029 genes), among which 703 alleles corresponding to 452 genes have given rise to the F₂ generation (Table 2; Supplemental Table S2).

Characterization of the features of the CRISPR/Cas9 target sequences

It is well known that the success rate of gene targeting via the CRISPR/Cas9 system is not 100%. Detectable mutations cannot be effectively induced at certain gRNA target sites, although no obvious rules could explain this phenomenon yet. To better understand the targeting capabilities of the CRISPR/Cas9 system in

zebrafish, we analyzed the features of CRISPR/Cas9 target sequences, based on the large amounts of gRNAs tested in this study.

GC-content distribution in tested target sites

All the tested gRNA target sites were collected for the analyses of target site features, including both “positive” ones (1086 in total that gave rise to mutations in F₀ fish) and “negative” ones (1191 in total that did not result in mutations in founder embryos) (Supplemental Table S1). We first compared the GC content between the two types of target sequences. The average GC content of all the tested target sites (the protospacer adjacent motif [PAM] sequence NGG was ignored, i.e., only protospacer sequences were used for the calculation) is 53.0%. The slightly high GC content could be partially explained by the presence of one or two Gs at the beginning of the target sequence, which is required for an efficient *in vitro* transcription of gRNAs by the T7 RNA polymerase. When only considering the more important 12-nucleotide (nt) seed sequence, the average GC content for all the target sites is reduced to 50.9%, close to expectation for unbiased design of target sequences. The GC content at the seed region is significantly higher in the 1086 positive target sites than in the 1191 negative ones, with 52.9%, on average, for the positive sites and 49.0%, on average, for the negative ones (Fig. 1A). This suggests that higher GC content in the seed region of the target site is more likely to result in successful mutation. This tendency can be seen more clearly when comparing the distribution of GC content at the seed region in the positive sites, where 70.4% (765/1086) of sites show GC content >50%, and that in the negative sites, where only 58.9% (703/1191) of sites show GC content >50% (Fig. 1B). In addition, this is revealed by the strong positive correlation of the success rate of targeting with the GC content of the seed sequences (Fig. 1B,C).

Figure 1. GC-content distribution in the 12-nt seed sequence of all the tested target sites (including 1086 positive sites and 1191 negative sites). (A) GC percentage of positive and negative target sites at the seed region, respectively. (B) GC percentage distribution of the seed region in all the tested target sites. GC count: number of G or C nucleotides in the 12-nucleotide (nt) seed sequence of the target sites. (C) Correlation of the positive rate of target sites with different GC percentages of the seed region. GC count: number of G or C nucleotides in the 12-nt seed sequence of the target sites.

Distribution of nucleotide motifs in tested target sites

Positions of nucleotides and nucleotide context might influence the targeting efficiency of the CRISPR/Cas9 system. We next assessed the base composition as well as the distribution of single nucleotides and nucleotide motifs in all the tested target sites. No significant difference was detected regarding single nucleotide distribution or ratio in the first 18 nt adjacent to the PAM region between the positive sequences and the negative ones, though there are variations among different nucleotides and at different positions (Fig. 2A; Supplemental Fig. S2), and the enrichment for G and C nucleotides in the positive sites is evident almost at every position (Supplemental Fig. S3). One of the few exceptions for this phenomenon is the composition of nucleotide C at position −1, the first nucleotide immediately upstream of the PAM, where negative sites are dominant for this nucleotide, suggesting that C at this position might have a negative impact on targeting efficiency (Supplemental Fig. S3D). The significantly high percentage of nucleotide G at the last two positions (−19 and −20 relative to the PAM) is due to the obligate requirement for the presence of two terminal Gs for efficient *in vitro* transcription of gRNAs by T7 RNA polymerase. The distribution of PAM sequences also did not show a significant difference between the positive and negative target sites, although GGG and CGG appear slightly more frequently in the positive sites than the negative ones (Supplemental Fig. S2A).

We further compared the distribution of 2-nt and 3-nt motifs in the tested target sites and their potential relationship with mutation rate. Among all the 16 different combinations of 2-nt motifs and 64 different 3-nt motifs, we found that target sites containing motifs such as “C/GC/G” dinucleotides or “C/GNC/G” trinucleotides are more likely to induce mutations (Fig. 2B,C). This observation is consistent with our GC content analysis mentioned above as well as a previous report showing that the activity of the CRISPR/Cas9 system is GC content-dependent (Labuhn et al. 2018).

Collection and distribution of the zko alleles

The F₂ fish lines resulting from the ZKO project were collected and their identities were confirmed by the China Zebrafish Resource Center (CZRC) (<http://en.zfish.cn>) through Sanger sequencing (Supplemental Data File S1). Sperm samples were obtained from the genotype-verified fish lines and frozen for cryopreservation. In 954 confirmed mutations (Supplemental Table S2), there are 24 big indels (>200 bp) with two gRNA targeting; thus, the rest of the 930 mutant alleles were analyzed for indel characteristics. The results showed that 61.4% (571/930) are deletions with an average size of 10.9 bp, 11.1% (103/930) are insertions with an average size of 6.4 bp, and 27.5% (256/930) are indels with an average insertion of 10.3 bp and deletion of 9 bp. In those 930 mutant alleles, 11.6% (108/930) are in-frame mutations and 88.4% (822/930) are frame-shift mutations.

A total of 693 alleles were successfully preserved by CZRC (Supplemental Table S3). All the nonsense zko alleles are listed at the websites of ZFIN (<http://zfin.org/action/publication/ZDB-PUB-171002-4/feature-list>) or CZRC (<http://www.zfish.cn/TargetList.aspx>). On the information page of each zko gene, the gene name, Ensembl ID, gRNA target site, target position, allele name, allele sequence, and a short description of the predicted protein product are shown. In addition, the detailed genome sequence flanking the target site, as well as a cluster analysis of the pairwise alignments (CLUSTAL) of the allele sequence and the wild-type genome sequence are presented as Portable

Among the identified mutants by the CRISPR/Cas9 system, we found that nearly one in four of the mutated genes in our study were associated with human diseases (Supplemental Table S1). For example, RUNX family transcription factor 1 (Runx1), which is encoded by *runx1*^{zkos2}, is essential for hematopoietic stem/progenitor cell (HSPC) production in the aorta-gonad-mesonephros (AGM) region during embryonic hematopoiesis. Extensive studies showed that abnormal *runx1* expression correlates with acute myeloid leukemia and platelet disorder (Rao 2013; Sood et al. 2017). We examined the hematopoietic phenotypes in the *runx1* mutants and found that *c-myb* (HSPC marker gene) expression in AGM at 36 hpf was decreased in these mutants compared to the control embryos (Supplemental Fig. S4A), which

Figure 3. Characterization of *plrg1* mutant generated by the CRISPR/Cas9 system. (A) Whole-mount in situ hybridization (WISH) showing the expression of *plrg1* at different developmental time points from the one-cell stage to 36 h postfertilization (hpf). (B) The comparison of genomic DNA sequences between wild type (WT) and *plrg1* mutants with 10-base pair deletion. (C) The *plrg1* mutants and morphants showed severe developmental defects, with black head and small body compared to the siblings and control embryos, respectively, at 24 hpf. (D) WISH showing the expression of *gsc* and *ntl* at the 50% epiboly stage, *sox17* at 90% epiboly stage, and *ntl* at bud stage in the offspring of *plrg1* heterozygous parents. The right panels show the magnified images, and the black arrowheads indicate corresponding expression of *gsc* at the dorsal margin, *ntl* at anterior axial hypoblast, forerunner cell group, and margin, and *sox17* at endoderm and forerunner cells. (E) WISH showing the expression of *lmo2*, *gata1*, and *scl* at lateral plate mesoderm in the siblings and *plrg1* mutants. (F) Overexpression of the *plrg1* full-length mRNA can rescue *plrg1* mutants until 4 dpf. The body defects of mutants were rescued efficiently by mRNA overexpression, but there is still a black head at 48 hpf (arrowhead) in *plrg1* mutants. (G) TUNEL assay displays that there are obvious apoptotic signals at 48 hpf in *plrg1* mutants injected with *plrg1* mRNA. (H) Injection of *tp53* morpholino can rescue the developmentally defective phenotype of *plrg1* mutants efficiently at 24 hpf. There are three subtypes of defective embryos, and we describe the siblings as normal, *plrg1* mutants as severe (S), and partial rescued mutants as mild (T1) and mild (T2). (I) The quantification of *plrg1* mutant embryos in different treatment groups shown in H.

is consistent with previously published data (Sood et al. 2010). In another example, zebrafish with *gyg2*^{zko624a} mutation displayed increased blood glucose content (Supplemental Fig. S4B). Similarly, *GYG2* mutation has been characterized as a pathogenic mutation in human Leigh syndrome, an early-onset progressive neurodegenerative disorder resulting from defective glycogen synthesis (Imagawa et al. 2014). Taken together, by following a conventional pipeline for phenotype identification of the generated mutants, we revealed a large number of previously uncharacterized phenotypes associated with development and disease.

Comparison between genetic mutants generated by CRISPR/Cas9 and their corresponding morphants by antisense MO knockdown

During the past two decades, reverse genetic approaches, including ZFNs, TALENs, and CRISPR/Cas9, have been developed rapidly and used extensively in genome editing and disease modeling

(Boch et al. 2009; Urnov et al. 2010; Jinek et al. 2012; Wiedenheft et al. 2012; Hwang et al. 2013). However, a large proportion of mutants generated by reverse genetics methods failed to recapitulate published morpholino-induced phenotypes (morphants) in zebrafish (Kok et al. 2015). Moreover, it was reported that genetic compensation can be induced by deleterious mutations (El-Brolosy et al. 2019; Ma et al. 2019), for example, as observed in zebrafish *egfl7* mutants (Rossi et al. 2015). We also observed phenotypes inconsistent between newly generated mutants and their corresponding morphants. For instance, the mutation of *dpy30*^{zko989}, encoding a histone methyltransferase complex subunit, showed no obvious phenotypes of hematopoietic cell differentiation (Supplemental Fig. S5A,B), which is inconsistent with the published morphant phenotypes that exhibit defective erythropoiesis and lymphopoiesis (Yang et al. 2014). In addition, transcriptional repressor Kruppel-like factor 3 (*Klf3*), which is encoded by *klf3*^{zko352}, can inhibit the expression of ferric-chelate

reductase 1b to promote the maturation of erythroid cells in zebrafish embryos (Crossley et al. 1996; Xue et al. 2015). The homozygous *klf3* mutant was able to survive until adulthood, and the maternal-zygotic *klf3* mutant (hereafter MZ-*klf3*) showed mild erythropoiesis defects (Fig. 4A). Quantitative real-time PCR analysis showed that *klf3* expression was significantly decreased in MZ-*klf3* at 24 hpf, whereas the expression of *klf1* was up-regulated (Fig. 4B). These data indicate that the inconsistent phenotype between *klf3* mutants and morphants could be explained by genetic compensation from other members of the Klf family in the *klf3* mutants.

Discussion

In this study, we performed large-scale knockout of 1333 genes on zebrafish Chromosome 1 and successfully mutated 1029 of them. Among them, 962 are coding genes and 67 are noncoding genes. Mutations for 438 genes are first reported in this study. We also characterized the features of target sequences and revealed correlation of GC content and nucleotide motifs with the successful mutation rate (success rate) of the CRISPR/Cas9 system. At the molecular level, we reveal that the efficiency of the CRISPR/Cas9 system is highly dependent on the local sequence feature of gRNA target sites. We noticed that 304 genes have not been successfully mutated in our study, which is possibly due to the fact that they are noncoding genes or genes that are close to the telomere. In total, we generated 1039 germline-transmissible alleles corresponding to 636 genes (Supplemental Table S2), of which the information on 693 alleles corresponding to 491 genes has been shared with the ZFIN database (Supplemental Table S2). As the first step, we identified the early morphological defects in 47 of 701 alleles; the detectable phenotype rate is 6.7%, such as in the *plrg1* mutant and in later developmental or metabolic phenotypes in a large number of mutants, such as *runx1^{zko52a}* and *gyg2^{zko624a}*. We found that some mutants exhibit phenotypes

inconsistent with their corresponding morphants. More importantly, we discovered that mutants of nearly one in four genes are related to human diseases.

Although there exist some differences, the overall tendencies of the sequence or mutagenesis features of the CRISPR/Cas9 target sites are largely comparable with previous publications based on zebrafish large-scale data sets. (1) Gagnon et al. observed a clear positive correlation between GC content and indel frequency in founder embryos (Gagnon et al. 2014), though Varshney et al. did not detect a significant influence of GC percentage on the mutation rate by examining the germline transmission of the mutations in founder fish (Varshney et al. 2015). We observed a strong positive correlation of the success rate of targeting with the GC content of the 12-nt seed sequences in our data set (Fig. 1), compatible with the result reported by Gagnon et al. (Gagnon et al. 2014). Furthermore, the positive influence of G/C nucleotides on targeting efficiencies was also supported by the observations reported by Moreno-Mateos et al., where nucleotides in the target sites were dominated by G or C enrichment, whereas T and A nucleotides were overall depleted (Moreno-Mateos et al. 2015). (2) We observed that the distribution of PAM sequences did not show significant differences between the positive and negative target sites, although GGG and CGG appear slightly more frequently in the positive sites than in the negative ones (Supplemental Fig. S2A), well reconciling the observation by Moreno-Mateos et al., where G and C were enriched at the first nucleotide of the PAM sequence (Moreno-Mateos et al. 2015). (3) Regarding the nucleotide at position -1 adjacent to (upstream of) the PAM sequence, our result showed that G is relatively enriched in the positive sites, while C is largely enriched in the negative sites (Supplemental Fig. S3C), which is consistent with the observations reported by Moreno-Mateos et al., where there is a strong enrichment for G but depletion in C at this position (Moreno-Mateos et al. 2015). This is also consistent with the observation reported by Gagnon et al., showing that target sites bearing a G adjacent to the PAM motif displayed significantly higher indel frequencies than other bases (Gagnon et al. 2014).

The most valuable resource obtained from this systematic gene perturbation project is the large number of disease-mimicked mutant phenotypes. For example, a recent study reveals that the deficiency of a cilia-related gene, *pkd2^{zko977a}*, in zebrafish embryos results in phenotypes similar to those of human idiopathic scoliosis (Zhang et al. 2018). Given that it is convenient to perform high-throughput drug screening and genetic modification for disease modeling in zebrafish (Langenau and Zon 2005; Jing and Zon 2011), the abundant disease models of model organisms provide a powerful platform for preclinical trials of drug development (Zon and Peterson 2005; MacRae and Peterson 2015; Leung and Mourrain 2016).

Molecularly, it is essential to further decipher the mechanisms underlying the inconsistency in phenotypes between mutants and morphants. Our finding in *klf3* mutants and morphants demonstrated that the compensatory up-regulation of *klf1* is largely responsible for the phenotypic recovery in *klf3* mutants. Genetic compensation (also known as transcriptional adaptation) is a common physiological phenomenon employed by organisms to accommodate genetic mutations mechanistically through DNA damage response and mutant RNA response (El-Brolosy and Stainier 2017; El-Brolosy et al. 2019; Ma et al. 2019). Additionally, it should be pointed out that maternal effects and MO off-target effects could also contribute to the phenotypic inconsistency (Kok et al. 2015; El-Brolosy and Stainier 2017).

Figure 4. Phenotypic comparison between *klf3* mutants and morphants. (A) WISH showing the expression of *hbbe2* (also known as β e2-globin) in *klf3* WT, morphants, and mutants. The black arrowheads indicate *hbbe2* expression in erythroid lineages. (B) Quantitative real-time PCR showing the expression of Klf members *klf1*, *klf3*, *klf4b*, *klf6a*, and *klf8* in *klf3* mutants.

Taken together, the results of our study provide valuable resources for mutant phenotype identification and disease model studies in zebrafish and provide insights into the general working mechanism of the CRISPR/Cas9 system. These findings can facilitate future gRNA design in developmental biology studies and model animal-based drug discovery.

Methods

Zebrafish strains

The zebrafish strain Tuebingen was raised in automated facilities at 28.5°C. One-cell stage embryos were used for micro-injection of Cas9 mRNA and gRNA. This study was approved by the Ethical Review Committees from the 24 institutions.

In vitro synthesis of capped Cas9 mRNA and gRNA, and microinjection

Sequences of humanized Cas9 and zebrafish-codon-optimized Cas9 were cloned into pXT7 vectors separately (Chang et al. 2013; Liu et al. 2014). Capped Cas9 mRNA was synthesized using the mMESSAGE mMACHINE mRNA transcription synthesis kit (Invitrogen, cat.# AM1344). Then, Cas9 mRNA was purified using an RNAClean kit (TIANGEN, cat.# DP412).

Gene-specific gRNAs were designed using the websites (<http://zifit.partners.org/ZiFiT/> and <https://www.benchling.com/crispr/>). gRNAs were synthesized in vitro with a PCR product-based approach, as previously reported (Chang et al. 2013). All tested gRNAs are listed in Supplemental Table S1.

Two hundred picograms of humanized Cas9 or zebrafish-codon-optimized Cas9 mRNA and 50–100 pg of gRNA were co-injected into zebrafish embryos at the one-cell stage.

Generation and identification of mutants, and phenotype observation

Direct embryo injection with gRNAs and Cas9 mRNA generates the F₀ line with mosaic mutation, which usually cannot result in embryonic lethality. Further outcross of the F₀ line with the wild-type line was performed to generate F₁ heterozygous lines. Finally, the F₂ mutant line with homozygous mutation was obtained via incross of F₁ heterozygotes.

F₀ embryos were identified by Sanger sequencing, T7E1 assay, and restriction enzyme digestion, and gRNA efficiencies were evaluated according to previous descriptions (Chang et al. 2013; Liu et al. 2014). Detailed information for heritable germline transmission strains can be found in Supplemental Table S2. The F₁ or F₂ mutant lines were genotyped through Sanger sequencing of PCR fragments covering the gRNA target sites. All the frame-shifted mutants were collected by the China Zebrafish Resource Center, and the genotype of each allele was verified by Sanger sequencing.

The male and female of the F₁ alleles with the same genotype were crossed to obtain F₂ progeny. The F₂ embryos were raised in 0.3× Danieau Buffer at 28.5°C and regularly observed under stereomicroscope for morphological defects before 10 d postfertilization.

Whole-mount in situ hybridization

Whole-mount in situ hybridization was performed as previously described (Wang et al. 2011). The Digoxigenin-labeled RNA probes detecting *plrg1*, *gsc*, *ntl*, *sox17*, *lmo2*, *gata1*, *scl*, *hbbe2*, *hbbe1*, *cmyb*, and *rag1* were transcribed using T7 or SP6 polymerase.

MO microinjection and mRNA overexpression

The antisense morpholinos including *plrg1* MO and *tp53* MO were purchased from GeneTools. The detail sequences are shown as follows: *plrg1* MO (5'-TGCTTCTGCACGTCCTCGGTTCATGT-3'), *tp53* MO (5'-GCGCCATTGCTTTGCAAGAATTG-3'). For injection into zebrafish embryos at the one- to four-cell stage, 0.16 ng *plrg1* MO and 4 ng *tp53* MO were used.

plrg1 full-length mRNA was synthesized from zebrafish cDNA using an mMESSAGE mMACHINE mRNA transcription synthesis kit (Invitrogen, cat.# AM1344). Then, *plrg1* mRNA was purified using an RNAClean kit (TIANGEN, cat.# DP412). Seventy-five picograms of *plrg1* mRNA was used for injection into zebrafish embryos at the one-cell stage.

Quantitative real-time PCR

Total RNAs from the whole embryos of siblings and mutants were extracted using TRIzol reagent (Life Technologies, cat.# 15596018). The cDNA was reversely transcribed from the total RNAs using M-MLV Reverse Transcriptase (Promega, cat.# M1701). Then, the cDNA was used as a template for quantitative real-time PCR.

TUNEL assay

A TUNEL assay was performed using an In Situ Death Detection kit, TMR red (Roche, cat.# 12156792910) following the manufacturer's instructions. Briefly, *plrg1* siblings and mutants at 48 h postfertilization were fixed with 4% paraformaldehyde and permeabilized with Proteinase K (10 µg/mL) for 20 min. Subsequently, the embryos were incubated with the TUNEL reaction mixture at 4°C. After the reaction, confocal microscopy was performed using a Nikon confocal A1 laser microscope (Nikon).

Data access

All the data related to available alleles from this study have been submitted to the China Zebrafish Resource Center (CZRC) at the following link: <http://www.zfish.cn/TargetList.aspx>, and to the Zebrafish Information Network (ZFIN) at the following link: <http://zfin.org/action/publication/ZDB-PUB-171002-4/feature-list>.

ZAKOC Consortium

Yonghua Sun,²⁶ Luyuan Pan,²⁶ Houpeng Wang,²⁶ Weixun Xie,²⁶ Mudan He,²⁶ Ding Ye,²⁶ Kuoyu Li,²⁶ Feng Xiong,²⁶ Liyue Liu,²⁶ Linglu Li,²⁶ Yun Zhang,²⁶ Bo Zhang,²⁷ Da Liu,²⁷ Zhenchao Cheng,²⁷ Yingying Hu,²⁷ Qian Wu,²⁷ Zhou Luo,²⁷ Yutian Zhang,²⁷ Yingdan Wu,²⁷ Wenyuan Li,²⁷ Lingfei Luo,²⁸ Jianlong Ma,²⁸ Dashuang Mo,²⁸ Pengcheng Cai,²⁸ Jinzi Chen,²⁸ Junhui Sun,²⁸ Yang Zhou,²⁸ Chuan Wu,²⁸ Rui Ni,²⁸ De-Li Shi,^{29,54} Ming Shao,²⁹ Yan-Jun Zhang,²⁹ Li-Jun Feng,²⁹ Xiao-Ning Cheng,^{29,54} Ji-Tong Li,²⁹ Yan-Yi Xing,²⁹ Yan Zhang,²⁹ Ya-Ping Meng,²⁹ Bei-Bei Yu,²⁹ Han Wang,³⁰ Jian Huang,³⁰

²⁶State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Innovation Academy of Seed Design, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China

²⁷Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, Peking University Genome Editing Research Center, College of Life Sciences, Peking University, Beijing, 100871, China

²⁸School of Life Sciences, Southwest University, Chongqing, 400715, China

²⁹School of Life Sciences, Shandong University, Qingdao, 266237, China

³⁰Center for Circadian Clocks, Soochow University, Suzhou, Jiangsu, 215123, China

Shuqing Zhang,³⁰ Cheng Ji,³⁰ Yicheng Tan,³⁰ Jingjing Wang,³⁰ Fanmiao Zhang,³⁰ Mingyong Wang,³⁰ Guodong Huang,³⁰ Zhaomin Zhong,³⁰ Wei Zhang,³⁰ Zongbin Cui,²⁶ Yong Long,²⁶ Guili Song,²⁶ Xiaohui Li,²⁶ Xixi Li,²⁶ Kai Chen,²⁶ Jing Ren,²⁶ Junjun Yan,²⁶ Qing Li,²⁶ Honghui Huang,²⁸ Hua Ruan,²⁸ Shicheng Zhu,²⁸ Xuejiao Chen,²⁸ Jingjing Pan,²⁸ Faming Jiang,²⁸ Jiehui Chen,²⁸ Chao Huang,²⁸ Guoping Dong,²⁸ Xiaogui Yi,²⁸ Ying Cao,³¹ Ruikun Hu,³¹ Weilai Huang,³¹ Jiangfang Liu,³¹ Hong WangXiao,³¹ Dong Shu,³² Jianhong Xia,³² Shaoyang Zhao,³² Pengtao Wang,³² Xiuhua Wu,³² Wenqing Zhang,³³ Yiyue Zhang,³³ Mengchang Xu,³³ Wei Liu,³³ Zhibing Huang,³³ Qing Lin,³³ Mei Wu,³³ Jianfeng Zhou,³⁴ Aibo Sheng,³⁴ Peipei Tang,³⁴ Xiaoxia Gong,³⁴ Wei Mou,³⁴ Congcong Zu,³⁴ Yun Li,³⁴ Ling Lu,³⁴ Yunzhang Liu,³⁴ Xiaozhi Rong,³⁴ Jianyang Chen,³⁴ Jiulin Du,³⁵ Jiwen Bu,³⁵ Xufei Du,³⁵ Tingting Liu,³⁵ Shanye Gu,³⁵ Qingshun Zhao,³⁶ Zhangji Dong,³⁶ Xiaohua Dong,³⁶ Shasha Cao,³⁶ Yunyun Yue,³⁶ Chun Gu,³⁶ Meijing Liu,³⁶ Jun Chen,³⁷ Hongjian Gong,³⁷ Hanbing Zhong,^{38,39} Xuanjun Yang,^{38,39} Jiahao Chen,³⁸ Qiushi Xu,³⁸ Tao P. Zhong,⁴⁰ Daqin Jin,⁴⁰ Peilu She,⁴⁰ Jianjian Sun,⁴⁰ Kaa Seng Lai,⁴⁰ Li Li,⁴⁰ Yu Zhang,²⁸ Yanyan Shi,²⁸ Fangying Zhao,²⁸ Jing-Wei Xiong,⁴¹ Meijun Pang,⁴¹ Lu Gao,⁴¹ Lei Lei,⁴¹ Jinrong Peng,⁴² Jane Lo,⁴² Wuhan Xiao,²⁶ Xiaolian Cai,²⁶ Gang Ouyang,²⁶ Jian Zhang,^{43,44} Weirui Ma,⁴⁵ Liyun Miao,⁴⁵ Jihua Yao,⁴⁶ Yu Hu,⁴⁶ Zhan Yin,²⁶ Xianming Mo,⁴⁷ Xue Li,⁴⁷ Gang Peng,⁴⁸ Cuizhen Zhang,⁴⁸ Fenghua Wang,⁴⁸ Jun Zhu,⁴⁹ Ruimeng Yang,⁴⁹ Hao Yuan,⁴⁹ Yan Chen,⁵⁰ Yi Pan,⁵⁰ Yong Zhou,⁵¹ Dong Liu,³⁸ Feng Zhao,³⁸

³¹School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China

³²Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, 510530, China

³³Division of Cell, Developmental and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China

³⁴School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, 266100, China

³⁵State Key Laboratory of Neuroscience, Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, 200031, China

³⁶Model Animal Research Center, Nanjing University, Nanjing, Jiangsu, 210093, China

³⁷College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, China

³⁸Department of Biology, South University of Science and Technology of China, Shenzhen, Guangdong, 518055, China

³⁹Institute of Chinese Medical Sciences, University of Macau, Macau, China

⁴⁰Institute of Biomedical Sciences, Shanghai Key Laboratory of Regulatory Biology, East China Normal University, Shanghai, 200062, China

⁴¹College of Life Sciences, Institute of Molecular Medicine, Peking University, Beijing, 100871, China

⁴²College of Animal Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, China

⁴³State Key Laboratory for Conservation and Utilization of Bio-Resources, Kunming, 650091, China

⁴⁴Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, 650091, China

⁴⁵State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China

⁴⁶School of Life Sciences, Fudan University, Shanghai, 200433, China

⁴⁷State Key Laboratory of Biotechnology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China

⁴⁸Institutes of Brain Science, Fudan University, Shanghai, 200433, China

⁴⁹Sino-French Research Center for Life Sciences and Genomics, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

⁵⁰Institute of Health Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

⁵¹CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, 200031, China

Weijun Pan,⁵⁰ Feng Liu,⁵² Yanyan Ding,⁵² Yuanyuan Xue,⁵² Lu Wang,⁵² Yifan Zhang,⁵² Dongyuan Ma,⁵² Xinyan Lu,⁵² Shuai Gao,⁵² Jun Xia,⁵² Zuoyan Zhu,²⁶ Anming Meng,⁵³ Xingfeng Liu,⁵³ Juhui Qiu,⁵³ Bo Gong,⁵³ Luxi Chen,⁵³ Cong Xiong,⁵³ Likun Yao,⁵³ Cencan Xing,⁵³ Yixia Wang,⁵³ Weimin Shen,⁵³ and Jiawei Sun⁵³

Acknowledgments

We thank all members of ZAKOC (Zebrafish All Genes KO Consortium for Chromosome 1) for the efforts contributed to this work. This work was supported by grants from the Ministry of Science and Technology of China (2018YFA0801000, 2018YFA0800200), the National Natural Science Foundation of China (31830061, 31721005), and the Strategic Priority Research Program of the Chinese Academy of Sciences, China.

Author contributions: F.L., Y.S., Z.Z., and A.M. conceived the project, analyzed the data, and wrote the paper with the help of other members of ZAKOC. All authors read and approved the final manuscript.

References

- Amsterdam A, Burgess S, Golling G, Chen W, Sun Z, Townsend K, Farrington S, Haldi M, Hopkins N. 1999. A large-scale insertional mutagenesis screen in zebrafish. *Genes Dev* **13**: 2713–2724. doi:10.1101/gad.13.20.2713
- Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. 2009. Breaking the code of DNA binding specificity of TAL-type III effectors. *Science* **326**: 1509–1512. doi:10.1126/science.1178811
- Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW, Xi JJ. 2013. Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos. *Cell Res* **23**: 465–472. doi:10.1038/cr.2013.45
- Crossley M, Whitelaw E, Perkins A, Williams G, Fujiwara Y, Orkin SH. 1996. Isolation and characterization of the cDNA encoding BKL/TEF-2, a major CACCC-box-binding protein in erythroid cells and selected other cells. *Mol Cell Biol* **16**: 1695–1705. doi:10.1128/MCB.16.4.1695
- Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, et al. 2008. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. *Nat Biotechnol* **26**: 702–708. doi:10.1038/nbt1409
- El-Brolosy MA, Stainier DYR. 2017. Genetic compensation: a phenomenon in search of mechanisms. *PLoS Genet* **13**: e1006780. doi:10.1371/journal.pgen.1006780
- El-Brolosy MA, Kontarakis Z, Rossi A, Kuenne C, Günther S, Fukuda N, Kikhi K, Boezio GLM, Takacs CM, Lai SL, et al. 2019. Genetic compensation triggered by mutant mRNA degradation. *Nature* **568**: 193–197. doi:10.1038/s41586-019-1064-z
- Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Pauli A, Montague TG, Zimmermann S, Richter C, Schier AF. 2014. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. *PLoS One* **9**: e98186. doi:10.1371/journal.pone.0098186
- Golling G, Amsterdam A, Sun Z, Antonelli M, Maldonado E, Chen W, Burgess S, Haldi M, Artzt K, Farrington S, et al. 2002. Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development. *Nat Genet* **31**: 135–140. doi:10.1038/ng896
- Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, et al. 2013. The zebrafish reference genome sequence and its relationship to the human genome. *Nature* **496**: 498–503. doi:10.1038/nature12111
- Huang P, Zhu Z, Lin S, Zhang B. 2012. Reverse genetic approaches in zebrafish. *J Genet Genomics* **39**: 421–433. doi:10.1016/j.jgg.2012.07.004
- Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. 2013. Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol* **31**: 227–229. doi:10.1038/nbt.2501

⁵²State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China

⁵³School of Life Sciences, Tsinghua University, Beijing, 100084, China

⁵⁴Present address: Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China

- Imagawa E, Osaka H, Yamashita A, Shiina M, Takahashi E, Sugie H, Nakashima M, Tsurusaki Y, Saito H, Ogata K, et al. 2014. A hemizygous *GYG2* mutation and Leigh syndrome: a possible link? *Hum Genet* **133**: 225–234. doi:10.1007/s00439-013-1372-6
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**: 816–821. doi:10.1126/science.1225829
- Jing L, Zon LI. 2011. Zebrafish as a model for normal and malignant hematopoiesis. *Dis Model Mech* **4**: 433–438. doi:10.1242/dmm.006791
- Kettleborough RN, Busch-Nentwich EM, Harvey SA, Dooley CM, de Bruijn E, van Eeden F, Sealy I, White RJ, Herd C, Nijman IJ, et al. 2013. A systematic genome-wide analysis of zebrafish protein-coding gene function. *Nature* **496**: 494–497. doi:10.1038/nature11992
- Kleinriders A, Pogoda HM, Irlenbusch S, Smyth N, Koncz C, Hammerschmidt M, Bruning JC. 2009. PLRG1 is an essential regulator of cell proliferation and apoptosis during vertebrate development and tissue homeostasis. *Mol Cell Biol* **29**: 3173–3185. doi:10.1128/MCB.01807-08
- Kok FO, Shin M, Ni CW, Gupta A, Grosse AS, van Impel A, Kirchmaier BC, Peterson-Maduro J, Kourkoulis G, Male I, et al. 2015. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. *Dev Cell* **32**: 97–108. doi:10.1016/j.devcel.2014.11.018
- Labuhn M, Adams FF, Ng M, Knoess S, Schambach A, Charpentier EM, Schwarzer A, Mateo JL, Klusmann JH, Heckl D. 2018. Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications. *Nucleic Acids Res* **46**: 1375–1385. doi:10.1093/nar/gkx1268
- Langenau DM, Zon LI. 2005. The zebrafish: a new model of T-cell and thymic development. *Nat Rev Immunol* **5**: 307–317. doi:10.1038/nri1590
- Leung LC, Mourrain P. 2016. Drug discovery: zebrafish uncover novel antipsychotics. *Nat Chem Biol* **12**: 468–469. doi:10.1038/nchembio.2114
- Li M, Zhao L, Page-McCaw PS, Chen W. 2016. Zebrafish genome engineering using the CRISPR-Cas9 system. *Trends Genet* **32**: 815–827. doi:10.1016/j.tig.2016.10.005
- Liu D, Wang Z, Xiao A, Zhang Y, Li W, Zu Y, Yao S, Lin S, Zhang B. 2014. Efficient gene targeting in zebrafish mediated by a zebrafish-codon-optimized *Cas9* and evaluation of off-targeting effect. *J Genet Genomics* **41**: 43–46. doi:10.1016/j.jgg.2013.11.004
- Ma Z, Zhu P, Shi H, Guo L, Zhang Q, Chen Y, Chen S, Zhang Z, Peng J, Chen J. 2019. PTC-bearing mRNA elicits a genetic compensation response via *Upf3a* and COMPASS components. *Nature* **568**: 259–263. doi:10.1038/s41586-019-1057-y
- MacRae CA, Peterson RT. 2015. Zebrafish as tools for drug discovery. *Nat Rev Drug Discov* **14**: 721–731. doi:10.1038/nrd4627
- Moore FE, Reyon D, Sander JD, Martinez SA, Blackburn JS, Khayter C, Ramirez CL, Joung JK, Langenau DM. 2012. Improved somatic mutagenesis in zebrafish using Transcription Activator-Like Effector Nucleases (TALENs). *PLoS One* **7**: e37877. doi:10.1371/journal.pone.0037877
- Moreno-Mateos MA, Vejnar CE, Beaudoin JD, Fernandez JP, Mis EK, Khokha MK, Giraldez AJ. 2015. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting *in vivo*. *Nat Methods* **12**: 982–988. doi:10.1038/nmeth.3543
- Rao AK. 2013. Spotlight on *FLII*, *RUNX1*, and platelet dysfunction. *Blood* **122**: 4004–4006. doi:10.1182/blood-2013-10-533166
- Rossi A, Kontarakis Z, Gerri C, Nolte H, Hölper S, Krüger M, Stainier DY. 2015. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature* **524**: 230–233. doi:10.1038/nature14580
- Solnica-Krezel L, Schier AF, Driever W. 1994. Efficient recovery of ENU-induced mutations from the zebrafish germline. *Genetics* **136**: 1401–1420.
- Sood R, English MA, Belele CL, Jin H, Bishop K, Haskins R, McKinney MC, Chahal J, Weinstein BM, Wen Z, et al. 2010. Development of multilineage adult hematopoiesis in the zebrafish with a *runx1* truncation mutation. *Blood* **115**: 2806–2809. doi:10.1182/blood-2009-08-236729
- Sood R, Kamikubo Y, Liu P. 2017. Role of *RUNX1* in hematological malignancies. *Blood* **129**: 2070–2082. doi:10.1182/blood-2016-10-687830
- Sorrells S, Carbonneau S, Harrington E, Chen AT, Hast B, Milash B, Pyati U, Major MB, Zhou Y, Zon LI, et al. 2012. *Cdc94* protects cells from ionizing radiation by inhibiting the expression of *p53*. *PLoS Genet* **8**: e1002922. doi:10.1371/journal.pgen.1002922
- Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. 2010. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet* **11**: 636–646. doi:10.1038/nrg2842
- Varshney GK, Lu J, Gildea DE, Huang H, Pei W, Yang Z, Huang SC, Schoenfeld D, Pho NH, Casero D, et al. 2013. A large-scale zebrafish gene knockout resource for the genome-wide study of gene function. *Genome Res* **23**: 727–735. doi:10.1101/gr.151464.112
- Varshney GK, Pei W, LaFave MC, Idol J, Xu L, Gallardo V, Carrington B, Bishop K, Jones M, Li M, et al. 2015. High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9. *Genome Res* **25**: 1030–1042. doi:10.1101/gr.186379.114
- Varshney GK, Carrington B, Pei W, Bishop K, Chen Z, Fan C, Xu L, Jones M, LaFave MC, Ledin J, et al. 2016. A high-throughput functional genomics workflow based on CRISPR/Cas9-mediated targeted mutagenesis in zebrafish. *Nat Protoc* **11**: 2357–2375. doi:10.1038/nprot.2016.141
- Wang L, Zhang PP, Wei YL, Gao Y, Patient R, Liu F. 2011. A blood flow-dependent *klf2a*-NO signaling cascade is required for stabilization of hematopoietic stem cell programming in zebrafish embryos. *Blood* **118**: 4102–4110. doi:10.1182/blood-2011-05-353235
- Wiedenheft B, Sternberg SH, Doudna JA. 2012. RNA-guided genetic silencing systems in bacteria and archaea. *Nature* **482**: 331–338. doi:10.1038/nature10886
- Wienholds E, van Eeden F, Kusters M, Mudde J, Plasterk RH, Cuppen E. 2003. Efficient target-selected mutagenesis in zebrafish. *Genome Res* **13**: 2700–2707. doi:10.1101/gr.1725103
- Xue Y, Gao S, Liu F. 2015. Genome-wide analysis of the zebrafish *Klf* family identifies two genes important for erythroid maturation. *Dev Biol* **403**: 115–127. doi:10.1016/j.ydbio.2015.05.015
- Yang Z, Augustin J, Chang C, Hu J, Shah K, Chang CW, Townes T, Jiang H. 2014. The *DPY30* subunit in *SET1/MLL* complexes regulates the proliferation and differentiation of hematopoietic progenitor cells. *Blood* **124**: 2025–2033. doi:10.1182/blood-2014-01-549220
- Zhang X, Jia S, Chen Z, Chong YL, Xie H, Feng D, Wu X, Song DZ, Roy S, Zhao C. 2018. Cilia-driven cerebrospinal fluid flow directs expression of urotensin neuropeptides to straighten the vertebrate body axis. *Nat Genet* **50**: 1666–1673. doi:10.1038/s41588-018-0260-3
- Zon LI, Peterson RT. 2005. *In vivo* drug discovery in the zebrafish. *Nat Rev Drug Discov* **4**: 35–44. doi:10.1038/nrd1606

Received January 22, 2019; accepted in revised form November 6, 2019.

Systematic genome editing of the genes on zebrafish Chromosome 1 by CRISPR/Cas9

Yonghua Sun, Bo Zhang, Lingfei Luo, et al.

Genome Res. 2020 30: 118-126 originally published online December 12, 2019

Access the most recent version at doi:[10.1101/gr.248559.119](https://doi.org/10.1101/gr.248559.119)

Supplemental Material <http://genome.cshlp.org/content/suppl/2019/12/12/gr.248559.119.DC1>

References This article cites 44 articles, 15 of which can be accessed free at:
<http://genome.cshlp.org/content/30/1/118.full.html#ref-list-1>

Open Access Freely available online through the *Genome Research* Open Access option.

Creative Commons License This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Affordable, Accurate
Sequencing.

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>